• Everolimus (RAD001): Measure the Right Response

  2026-08-15

  Everolimus (RAD001) can suppress proliferation without directly proving cell death. This evidence-based guide applies Schwartz’s relative-versus-fractional viability framework to mTOR experiments, helping researchers interpret cancer cell proliferation inhibition, apoptosis assay results, and translational potency more accurately.

• Capecitabine in Patient-Derived Tumor Assembloids

  2026-08-14

  Capecitabine is a fluoropyrimidine prodrug whose apparent activity depends on enzymatic activation and tumor context. This article explains how patient-derived gastric cancer assembloids can improve interpretation of drug response, stromal resistance, and apoptosis-oriented assays in preclinical oncology research.

• PDHA1 Succinylation and Macrophage Immune Escape

  2026-08-14

  A 2025 Nature Communications study identifies PDHA1 K83 succinylation as a metabolic–immune link in cholangiocarcinoma. The work shows that altered PDH activity increases tumor-microenvironment α-KG, suppresses macrophage MHC-II antigen presentation through OXGR1–MAPK signaling, and may create a rationale for combining CPI-613 with gemcitabine and cisplatin.

• Epacadostat: An IDO1 Assay-to-Immunity Framework

  2026-08-13

  Epacadostat (INCB024360) is examined through an assay-to-immunity framework that connects IDO1 biochemical potency with cellular and whole-blood immune readouts. Learn how to interpret matrix effects, cytokine changes, and checkpoint-inhibitor combination studies without overstating translational evidence.

• Losmapimod in p38 MAPK Research Workflows

  2026-08-13

  Losmapimod (GW856553X) enables coordinated studies of p38α/β inhibition, inflammatory signaling, and vascular biology rather than relying on a single endpoint. This workflow-centered guide shows how to pair kinase inhibition with phosphatase and pathway readouts while avoiding common solubility, timing, and interpretation errors.

• Bestatin Hydrochloride: An Assay Design Guide

  2026-08-12

  Bestatin hydrochloride (Ubenimex) is more than a broad aminopeptidase inhibitor: it can function as a pathway-dissection tool. This guide connects classic angiotensin neurophysiology with angiogenesis inhibition, tumor growth and invasion research, and practical assay design.

• DPI: A Strategic Probe for Redox-cAMP Biology

  2026-08-12

  Diphenyleneiodonium chloride is more than a conventional NADH oxidase inhibitor: its redox-enzyme activity and GPR3-linked cAMP effects create both a powerful experimental opportunity and a major interpretation challenge. This thought-leadership guide connects DPI-enabled pathway dissection with recent evidence that iron, reactive oxygen species, and ferroptosis-like defense can shape plant–pathogen resistance.

• CPI-613 and Tumor–Immune Metabolic Reprogramming

  2026-08-11

  CPI-613 links mitochondrial enzyme inhibition with tumor–immune metabolic research. This article interprets new cholangiocarcinoma findings and translates them into practical assay, control, and combination-treatment decisions.

• RapaLink-1: A Precision mTOR Resistance Tool

  2026-08-11

  RapaLink-1 is a third-generation mTOR inhibitor engineered to address resistance at both allosteric and kinase-domain binding sites. This article presents an assay-centered framework for interpreting mTORC1 inhibition, glioma phenotypes, and reversible dormancy without confusing reduced proliferation with irreversible cell death.

• Suhuang, ER Stress, and NLRP3 in Cough Variant Asthma

  2026-08-10

  The reference study links endoplasmic reticulum stress to NLRP3 inflammasome activation and pulmonary dysfunction in an ovalbumin-induced model of cough variant asthma. Its main contribution is a mechanistic pathway connecting calcium trafficking, PKCε, TXNIP, and the RIP1-RIP3-Drp1 axis, while showing that Suhuang antitussive capsule protects pulmonary homeostasis through ER-stress suppression.

• CP-673451 PDGFRα/β Assay Workflows

  2026-08-09

  CP-673451 is a selective PDGFRα/β inhibitor for separating PDGF-driven signaling from broader receptor tyrosine kinase effects. This guide translates its biochemical potency into reproducible phosphorylation, angiogenesis, ATRX-stratified glioma, and xenograft research workflows.

• Radicicol Hsp90 Inhibitor Workflows

  2026-08-08

  Radicicol is a mechanistic Hsp90 inhibitor for dissecting antigen cross-presentation, adipocyte differentiation, apoptosis, and inflammatory signaling. This practical guide connects target-selective assay design with formulation, dosing, controls, and troubleshooting across cellular and in vivo models.

• PHF2, Neuroinflammation, and Alzheimer’s Disease

  2026-08-07

  Yang and colleagues identify the histone demethylase PHF2 as an epigenetic regulator of inflammatory gene expression in Alzheimer’s disease. Across human tissue, patient-derived neurons, and 5xFAD mice, PHF2 reduction was associated with lower neuroinflammation, improved synaptic function, and better spatial memory, while also highlighting important limits for therapeutic translation.

• Imatinib Hydrochloride in Cancer Research: Optimizing Workfl

  2026-08-07

  Imatinib hydrochloride (STI571 hydrochloride) stands as a gold-standard, multi-target tyrosine kinase inhibitor empowering translational cancer research. This article delivers practical protocol enhancements, troubleshooting strategies, and key mechanistic insights to maximize the reproducibility and impact of chronic myelogenous leukemia and gastrointestinal stromal tumor studies.

• Tivozanib (AV-951): Precision VEGFR Inhibition in Cancer Ass

  2026-08-06

  Explore how Tivozanib (AV-951) enables ultra-selective VEGFR signaling pathway inhibition for advanced anti-angiogenic therapy research. This article reveals mechanistic insights, rigorous protocol parameters, and new perspectives for optimizing renal cell carcinoma treatment models.

16726 records 1/1116 page Next 12345 下5页 Last page